Cefpirome sulfate
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03973 |
| CAS | 98753-19-6 |
| Molecular Weight | 612.66 |
| Molecular Formula | C22H24N6O9S3 |
| Purity | 95% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-03973 | 5 g | $159 | In stock |
Online Inquiry
Add to cartDescription
Cefpirome Sulfate is a fourth generation cephalosporin antibiotic. It was developed by German company Hoechst and France Roussel company together.
Specification
| Synonyms | 1-[[(6R,7R)-7-[[(2z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-5h-cyclopenta[b]pyridinium sulfate |
| Shelf Life | 2 month in rt, long time |
| Storage | Store at 2-8°C |
| IUPAC Name | (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;sulfuric acid |
| Canonical SMILES | CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)O.OS(=O)(=O)[O-] |
| InChI | InChI=1S/C22H22N6O5S2.H2O4S/c1-33-26-15(13-10-35-22(23)24-13)18(29)25-16-19(30)28-17(21(31)32)12(9-34-20(16)28)8-27-7-3-5-11-4-2-6-14(11)27;1-5(2,3)4/h3,5,7,10,16,20H,2,4,6,8-9H2,1H3,(H3-,23,24,25,29,31,32);(H2,1,2,3,4)/t16-,20-;/m1./s1 |
| InChI Key | RKTNPKZEPLCLSF-KYSFMIDTSA-N |
| Source | Mixture |
Properties
| Appearance | White Solid |
| Application | beta Lactam Antibiotics |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Gram-negative bacteria |
| Melting Point | 198-202°C |
| Solubility | Soluble in DMSO (44 mg/ml) |
Reference Reading
1.The erratic antibiotic susceptibility patterns of bacterial pathogens causing urinary tract infections.
Ahmed I1, Sajed M1, Sultan A1, Murtaza I1, Yousaf S2, Maqsood B3, Vanhara P4, Anees M5. EXCLI J. 2015 Aug 4;14:916-25. doi: 10.17179/excli2015-207. eCollection 2015.
Increasing trend of antibiotic resistance and expression of Extended Spectrum Beta Lactamases (ESBLs) are serious threats for public health as they render the treatment ineffective. Present study was designed to elucidate the antibiotic-susceptibility patterns of ESBL and non-ESBL producing E. coli and K. pneumoniae causing urinary tract infections so that the ineffective antibiotics could be removed from the line of treatment. The bacterial isolates obtained from the urine of patients visiting a tertiary health care facility were cultured for strain identification using API20E. Antimicrobial susceptibility and ESBL detection were done by Kirby-bauer diffusion technique. Almost 53.4 % isolates of E. coli and 24.5 % isolates of K. pneumoniae were found to be ESBL producers. The ESBL producing bacteria were found to be more resistant towards various antibiotics. The most effective drugs against E. coli ESBL isolates were imipenem (99.54 %), ampicillin-sulbactam (97.
2.Development and validation of stability-indicating HPLC method for determination of cefpirome sulfate.
Zalewski P, Skibiński R, Cielecka-Piontek J, Bednarek-Rajewska K. Acta Pol Pharm. 2014 Sep-Oct;71(5):731-6.
The stability-indicating LC assay method was developed and validated for quantitative determination of cefpirome sulfate (CPS) in the presence of degradation products formed during the forced degradation studies. An isocratic HPLC method was developed with Lichrospher RP-18 column, 5 μm particle size, 125 mm x 4 mm column and 12 mM ammonium acetate-acetonitrile (90 : 10 v/v) as a mobile phase. The flow rate of the mobile phase was 1.0 mL/min. Detection wavelength was 270 nm and temperature was 30 degrees C. Cefpirome sulfate as other cephalosporins was subjected to stress conditions of degradation in aqueous solutions including hydrolysis, oxidation, photolysis and thermal degradation. The developed method was validated with regard to linearity, accuracy, precision, selectivity and robustness. The method was applied successfully for identification and determination of cefpirome sulfate in pharmaceuticals and during kinetic studies.
3.Clinical manifestations and bacteriological features of culture-proven Gram-negative bacterial arthritis.
Lin WT1, Tang HJ2, Lai CC3, Chao CM4. J Microbiol Immunol Infect. 2015 Sep 18. pii: S1684-1182(15)00850-6. doi: 10.1016/j.jmii.2015.08.026. [Epub ahead of print]
BACKGROUND/PURPOSE: To investigate the clinical manifestations and bacteriological features of culture-proven, Gram-negative bacterial arthritis.
4.Antibiotic resistance in wastewater: occurrence and fate of Enterobacteriaceae producers of class A and class C β-lactamases.
Amador PP1, Fernandes RM, Prudêncio MC, Barreto MP, Duarte IM. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2015;50(1):26-39. doi: 10.1080/10934529.2015.964602.
Antibiotics have been intensively used over the last decades in human and animal therapy and livestock, resulting in serious environmental and public health problems, namely due to the antibiotic residues concentration in wastewaters and to the development of antibiotic-resistant bacteria. This study aimed to access the contribution of some anthropological activities, namely urban household, hospital and a wastewater treatment plant, to the spread of antibiotic resistances in the treated wastewater released into the Mondego River, Coimbra, Portugal. Six sampling sites were selected in the wastewater network and in the river. The ampicillin-resistant Enterobacteriaceae of the water samples were enumerated, isolated and phenotypically characterized in relation to their resistance profile to 13 antibiotics. Some isolates were identified into species level and investigated for the presence of class A and class C -lactamases. Results revealed high frequency of resistance to the -lactam group, cefoxitin (53.
Recommended Products
| BBF-03753 | Baicalin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
